remains less favorable. 5 Flexible stents with a greater trackability emphasize this development.
the passage of the lesion with a Crown stent did not succeed, NIR stent implantation was tried or inverted. All stents were prospectively implanted with high-pressure balloon expansion under online angiographic assessment of the final stent expansion. The poststenting treatment consisted of ticlopidine and aspirin. The indication for stent implantation after previous balloon angioplasty was (1) abrupt or threatening vessel occlusion defined as a dissection of the artery with compromised antegrade blood flow (Thrombolysis in Myocardial Infarction [TIMI] grade <3) or (2) vessel dissection without compromised antegrade blood flow but at high risk for subacute occlusion and early restenosis or (3) unsatisfactory angioplasty result with >30% residual stenosis measured by online quantitative coronary analysis (QCA) or (4) elective stent implantation for treatment of de novo lesions in proximal segments of the target artery or restenotic lesions or lesions in bypass grafts.
The study protocol was approved by the local ethics committee, and written informed consent was obtained from all patients for the stent implantation procedure and for a followup angiography 6 months after the procedure.
Stent placement
All procedures were performed with a large-lumen 6F guiding catheter (Ascent, Medtronic Interventional Vascular, Kerkrade, The Netherlands) through a femoral approach. All patients received oral aspirin (100 mg) and 10,000 IU heparin at the start of the procedure. After balloon dilatation with low-profile, rapid-exchange balloon catheters (Europass, Cordis Europa NV, Roden, The Netherlands) with sizes according to the normal segment of the target vessel, the decision for stent placement was made by the operator according to the above criteria. If the decision for stent implantation was made, one or more J&J Crown stents (slotted stainless-steel tube) or one or more NIR stents (edged, folded and welded stainless steel) were manually crimped on the previously used balloon catheter. The NIR stents used in this study contain 7 attached cells in circumference for impantation in smaller vessels (2-3.5 mm). After deployment of the stent inside the target lesion, high-pressure stent expansion with at least 13 atmospheres was performed. By use of semicompliant balloons, a 10% oversizing of the stented segment was achieved. The procedure was terminated if the residual stenosis measured by online QCA was <10%. The femoral sheath was removed after normalization (<40 seconds) of the partial thromboplastin time. Immediately after stent implantation, additional antithrombotic treatment with ticlopidine 250 mg twice daily was started and continued for 4 weeks. Low-molecular-weight heparin was administrated subcutaneously 48 hours after the intervention until a complete ticlopidine atithrombotic effect was achieved. Aspirin was continued indefinitely.
End points
The primary end points were the restenosis rate (defined as >50% vessel diameter at follow-up) and minimal luminal diameter at follow-up.
The secondary end points were death, myocardial infarction, need for emergency coronary artery bypass grafting (CABG), and a second intervention involving the previously dilated vessel between the time of randomization and the follow-up angiography performed 6 months later.
Angiographic analysis
Three angiograms in at least 2 orthogonal views were obtained for each patient: 1 before the intervention, 1 immediately after, and 1 at follow-up 6 months later. Intracoronary nitroglycerin (200 µg) was injected before angiographic assessment. Quantitative analysis with a validated edge-detection system (DCI, Philips Medical Systems, Best, The Netherlands) 7 was performed online during the procedure and routinely before, after, and at follow-up. Angiograms were evaluated by 2 senior cardiologists blinded to the implanted stent and not personally involved in the stenting procedure of study patients. The treated segment at follow-up was determined by an exact comparison with the prior intervention. The diameter of the normal segment proximal to the treated area in at least 2 orthogonal views was averaged to determine the reference diameter.
Definition and clinical follow-up
Current smoker was defined as smoking ≥10 cigarettes per day, hypertension as systolic blood pressure >160 mm Hg or diastolic blood pressure >90 mm Hg, hypercholesterolemia as cholesterol >200 mg/dL or high-density lipoprotein cholesterol >35 mg/dL, or low-density lipoprotein cholesterol >150 mg/dL. Angiographic success was defined as a <10% residual diameter stenosis of the stented artery. Adverse clinical events were (1) acute or threatened vessel occlusion with compromised antegrade flow of the target vessel (TIMI grade <3) complicating angioplasty and requiring repeat angioplasty, (2) elective or emergency CABG, (3) myocardial infarction, defined as combination of chest pain lasting >30 minutes, new Q waves lasting ≥0.04 seconds or ST-segment elevation (>0.1 mV) in at least 2 contiguous leads on the electrocardiogram (ECG) measured immediately after the procedure and 6 and 24 hours later and a more than 2-fold increase in creatine phosphokinase above baseline after 6, 12, and 24 hours, and (4) cardiac death.
All patients who survived to hospital discharge were followed up for at least 6 months after discharge.
Follow-up
Coronary angiography was required routinely at 6 months after stent implantation in all patients except those who had clinical symptoms of recurrent ischemia documented by angina, ECG abnormalities at exercise or at rest, or positive thallium stress testing. In those patients angiography was performed when restenosis was clinically suspected. Nine patients who have received NIR stents and 8 patients who have received J&J Crown stents declined follow-up angiography because of lack of angina. Only patients with a complete follow-up angiogram were included for final analysis.
Statistical analysis
All analyses were performed on the intention-to-treat basis. The required sample size was based on an assumed restenosis rate of 30% in the group receiving NIR stents and a reduction of that rate by 50% in the group undergoing J&J Crown stent implantation by an α error of .05 and a power of 80%. Data are reported as mean ± SD. Continuous variables were compared by the Student t test for independent samples. The Wilcoxon test was used for categorical variables. A χ 2 test or the Fisher exact test (for cells <5) was used to determine the 2-tailed statistical significance of associations in 2-by-2 tables. P values <.05 were considered to indicate statistical significance. Data management and analysis was performed by the STATISTICA for Windows software package release 5.5, 1999 edition (StatSoft, Tulsa, Okla).
Results
Between October 1995 and April 1997, 220 patients with symptomatic coronary artery disease underwent coronary stent implantation according to the above criteria. A total of 203 of 220 completed the follow-up angiography (92.3%) and were included for the final analysis; 99 of 103 (99%) patients received one or more (1.1 ± 0.36) J&J Crown stents, and 99 of 100 (99%) patients received one or more (1.2 ± 0.46) NIR stents. In 4 of 203 (2%) patients stent implantation did not succeed. Procedural success was equal in both groups (P = .19). The indication for stent implantation was evenly distributed between groups; 25 of 103 (24%) in the J&J Crown stent group and 26 of 100 (26%) in the NIR stent group were treated with a glycoprotein IIb/IIIa inhibitor (P = .78).
There were no statistical differences between groups regarding their clinical characteristics (Table I) . Angiographic findings, such as target vessel distribution and stenosis type were similar in both groups (Table II) .
Five patients in each group had a repeat angiography because of angina without the need for further interventions. In 4 cases J&J Crown stent implantation did not succeed. Three of the patients were treated with NIR stent implantation. In 1 patient implantation of neither the J&J Crown nor the NIR stent was possible because of target vessel morphologic features. This patient had a postprocedural myocardial infarction (creatine kinase [CK] maximum 266 U/L) without further complications. One patient in the J&J Crown stent group died after a fulminant pulmonary embolism 3 weeks after the initial procedure (Table III) .
Angiographie results
The results of quantitative coronary angiography are shown in Table IV . The only significant difference between groups was the different stent length (22.5 ± 9.1 vs 26.3 ± 12.9 in the NIR stent group, respectively; P = .021). Follow-up angiography 5.8 ± 1.3 months after the initial procedure revealed no statistical difference in measured angiographic variables.
Restenosis, defined as >50% diameter stenosis at follow-up occurred in 19 patients (18.4%) in the J&J Crown stent group compared with 22 patients (22%) in the NIR stent group (P = .42).
Discussion
The current randomized clinical study shows no longterm differences in angiographic variables nor in clini- cal outcome in patients receiving 2 different flexible stents, the J&J Crown and the NIR stent. For the sample size calculation a significant difference was assumed between the J&J Crown stent made out of the same material like the Palmaz-Schatz stent (slotted stainlesssteel tube) for which reduction of restenosis was already approved 1,2 compared with the NIR stent produced with a different production process (edged, folded, and welded stainless steel). Previous trials investigated the influence of geometric features of used stents on the development of coronary restenosis. Although the number of implanted stents was not found to worsen clinical outcome, 8 stented segment length represents an independent predictor of restenosis. 9 High balloon pressure inflation during coronary stenting has been shown not to influence the 1-year outcome after the intervention. 10 These to some extent contradictory results focused on whether the stent type influences long-term angiographic and clinical outcome.
We found no clinically important differences comparing 2 multicellular stents. Both the angiographic and the clinical long-term outcomes were similar in both groups. The only significant difference was the length of the implanted stent. In the NIR stent group, significantly longer stents were implanted, resulting in a slightly larger late luminal loss and consecutively reduced net gain without influencing significantly either minimal luminal diameter or restenosis rate at follow-up.
The impact of stent design on the development of intimal hyperplasia or smooth muscle cell proliferation is unknown, although previous reports in an animal model could not find differences between different materials in platelet and fibrin deposition resulting in luminal renarrowing. 11 The tissue answer caused by the coronary interventions seems to be uniform and depends on concomitant diseases. 12 Stent design and geometry by themselves generally influence in-stent restenosis in a different manner. 13, 14 The J&J Crown stent is slightly more rigid, resulting in a significantly higher rate of crossover to the NIR stent (3.9% vs 0%, respectively, P = .047). The one lesion in which NIR stent implantation was not successful had an extremely tortuous proximal part. This patient underwent only balloon angioplasty. A good method of tracking of the used stent appears very important during routine interventions because it enables the cardiologist to treat even complex lesions, especially in cases with threatening vessel occlusion complicating angioplasty.
Limitations of the study
The main limitation of the current study was the lack of power. The assumed 30% restenosis rate in the NIR stent group results from recent studies. 15 The observed lower restenosis rates are due to the progress in stent technology, which we could not anticipate. There is no limitation of presented results related to the incomplete follow-up because the required sample size was calculated with a 10% lack of follow-up angiography.
Intravascular ultrasonographic data about plaque morphologic features before stent implantation and plaque geometry in cases of in-stent restenosis are not available. Therefore the mode of the tissue answer after stenting remains speculative. However, the angiographic data represent an applicable criterion for the comparison of different stents. 16 
Conclusion
There were no significant angiographic and clinical differences between the J&J Crown stent and the NIR stent. Both stents had a similar procedural success rate, although the implantation of NIR stents was successful even in vessels in which previous attempts of J&J Crown stent placement had failed. The very small incidence of target vessel revascularization was probably by chance and a result of the small sample size. 
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